Here’s Exactly Where We’re At With Vaccines and Treatments for COVID-19

  • Scientists around the world are working on potential treatments and vaccines for the coronavirus disease known as COVID-19.
  • Several companies are working on antiviral drugs, some of which are already in use against other illnesses, to treat people who already have COVID-19.
  • Other companies are working on vaccines that could be used as a preventive measure against the disease.
  • It will probably take months, if not more than a year, for a drug or vaccine to complete clinical trials and be available to the public.

With COVID-19 cases worldwide passing the 200,000 mark and continuing to grow, scientists are pushing forward with efforts to develop vaccines and treatments to slow the pandemic and lessen its damage.

Some of the earliest treatments will likely be drugs that are already approved for other conditions or have been tested on other viruses.

“People are looking into whether existing antivirals might work or whether new drugs could be developed to try to tackle the virus,” said Dr. Bruce Y. Lee, a professor of health policy and management at City University of New York.

Still, there’s only so much that vaccine and drug development can be sped up, even with improvements in genetic sequencing and other technologies.

“Even though technological advances allow us to do certain things more quickly,” Lee told Healthline, “we still have to rely on social distancing, contact tracing, self-isolation, and other measures.”

Here’s a rundown of the latest COVID-19 vaccine and drug developments.


Several companies are developing or testing antivirals against the virus that causes COVID-19.

Antivirals target the virus in people who already have an infection. They work in different ways, sometimes preventing the virus from replicating, other times blocking it from infecting cells.

Lee says antivirals work better if you administer them sooner, “before the virus has a chance to multiply significantly.”

And also before the virus has caused significant damage to the body, such as to the lungs or other tissues.

Dr. Robert Amler, dean of the School of Health Sciences and Practice at New York Medical College and former chief medical officer at the Centers for Disease Control and Prevention (CDC), says both antivirals and vaccines will be valuable tools in combating COVID-19.

However, he told Healthline that “antivirals are likely to be developed and approved before a vaccine, which typically takes longer.”

Drug development is sometimes described as a pipeline with compounds moving from early laboratory development to laboratory and animal testing to clinical trials in people.

It can take a decade or more for a new compound to go from initial discovery to the marketplace. Many compounds never even make it that far.

That’s why antivirals being eyed as treatments for COVID-19 are drugs that already exist. They include:

  • Remdesivir. Developed a decade ago, this drug failed in clinical trials against Ebola in 2014. But it was found to be generally safe in people. Research with MERS showed that the drug blocked the virus from replicating. It’s now being tested in five COVID-19 clinical trials. The first results should be available in April.
  • Kaletra. This is a combination of two drugs that work against HIV. Clinical trials are planned to see whether it works against the virus that causes COVID-19.
  • Chloroquine. Initial laboratory studies show that this antimalarial drug may work against the COVID-19 virus by blocking infection. A small clinical trial of this drug in France suggests it may work as a treatment for COVID-19. However, the study wasn’t randomized, so larger clinical trials will be needed. Researchers at the University of Queensland in Australia expect to start a clinical trial of chloroquine and an HIV drug later this month.
  • Favipiravir. This drug is approved in some countries outside the United States to treat influenza. Some reports from China suggest it may work as a treatment for COVID-19. These results, though, have not been published yet.

Scientists are also looking at other ways to target the virus or treat the complications of COVID-19, such as:

  • Monoclonal antibodies. These drugs trigger the immune system to attack the virus. Vir Biotechnology has isolated antibodies from patients who survived SARS. The company is working with Chinese firm WuXi Biologics to test them as a treatment for COVID-19. AbCellera has isolated 500 unique antibodies from a person who recovered from COVID-19 and is set to start testing them.
  • Stem cells. Athersys Inc. released preliminary data last year showing that its stem cell treatment could potentially benefit people with acute respiratory distress syndrome (ARDS). This condition occurs in some people with severe COVID-19. Mesoblast tested its stem cell product in a small group of people with COVID-19 with positive results.

While a lot of the focus is on developing new treatments for COVID-19, improvements in how doctors care for patients using existing technology are also crucial.

“The things that we have to worry about with the novel coronavirus is that it can cause pneumonia and acute respiratory distress syndrome,” Lee said. “There are ways of treating those things that can reduce the effects, so doctors are trying to use those as well.”

No company has offered a timeline for when its drug might be used more widely to treat COVID-19. This isn’t an easy thing to estimate.

After laboratory and animal testing, drugs have to pass through several clinical trial stages before they can be approved for widespread use in people.

It’s also difficult to speed things up, because scientists have to enroll enough people in each stage to have useful results. They also have to wait long enough to see whether there are harmful side effects of the drug.

However, drugs can sometimes be given to people outside a clinical trial through the Food and Drug Administration’s “compassionate use” program. For this to happen, people must have an “immediately life-threatening condition or serious disease or condition.”

Doctors at the University of California, Davis were able to secure this type of approval for a woman with severe COVID-19 to receive remdesivir. They report that she’s now doing well.

Many will take this as a sign that the drug works. But because the drug was given outside of a clinical trial to just one person, it’s not possible to know for certain. Also, other people may not have the same response to the drug.

Clinical trial stages

  • Phase I. The drug is given to a small number of healthy people and people with a disease to look for side effects and figure out the best dose.
  • Phase II. The drug is given to several hundred people who have the disease, looking to see whether it works and if there are any side effects that weren’t caught during the initial testing.
  • Phase III. In this large-scale trial, the drug is given to several hundred or even up to 3,000 people. A similar group of people take a placebo, or inactive compound. The trial is usually randomized and can take 1 to 4 years. This stage provides the best evidence of how the drug works and the most common side effects.
  • Phase IV. Drugs that are approved for use undergo continued monitoring to make sure there are no other side effects, especially serious or long-term ones.


A vaccine is designed to protect people before they’re exposed to a virus — in this case, SARS-CoV-2, the virus that causes COVID-19.

A vaccine basically trains the immune system to recognize and attack the virus when it encounters it.

Vaccines protect both the person who’s vaccinated and the community. People who are vaccinated can’t become infected with a virus, which means they can’t pass it to others. This is known as herd immunity.

Many groups are working on potential vaccines for SARS-CoV-2, with several backed by the nonprofit Coalition for Epidemic Preparedness Innovations (CEPI).

Several of these groups started their work shortly after Chinese scientists shared the genetic sequence of the virus. These include:

  • Moderna. This week, the company began testing its messenger RNA (mRNA) vaccine in a phase I clinical trial in Seattle, Washington. The study includes 45 healthy volunteers, ages 18 to 55. The company has developed other mRNA vaccines before. Those earlier studies showed that their platform is safe, which allowed the company to skip certain animal testing for this specific vaccine.
  • Inovio. When COVID-19 appeared in December, the company had already been working on a DNA vaccine for MERS, which is caused by another coronavirus. This allowed the company to quickly develop a potential vaccine for the COVID-19 virus. The company is expected to start clinical trials for its new vaccine next month.
  • University of Queensland in Australia. Researchers are developing a vaccine by growing viral proteins in cell cultures. They expect to start clinical trials later this month.
  • Pharmaceutical companies. Johnson & Johnson and Sanofi are both working on a vaccine of their own.

Advances in genetic sequencing and other technological developments have sped up some of the earlier laboratory work for vaccine development.

However, Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, told reporters last week that a vaccine won’t be available for widespread use for at least another 12 to 18 months.

This is the timeline to complete the phase III clinical studies. There’s no guarantee that the vaccine candidates will work.

“There’s a lot of uncertainty with vaccine development,” Lee said. “Naturally, you have to make sure the vaccine is safe. But you also have to make sure the vaccine will elicit enough of an immune response.”

Like drugs, potential vaccines have to pass through the same clinical trial stages. This is especially important when it comes to safety, even during a pandemic.

“The public’s willingness to back quarantines and other public-health measures to slow spread tends to correlate with how much people trust the government’s health advice,” Shibo Jiang, a virologist at Fudan University in China, wrote in the journal Nature.

“A rush into potentially risky vaccines and therapies will betray that trust and discourage work to develop better assessments,” he said.

Source: Read Full Article